Navigation Links
BioMS Medical to present at BioContact 2007
Date:9/28/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 28 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President Corporate Affairs, will give a corporate presentation at BioContact 2007 in Quebec City.

WHEN: Wednesday 3rd October, 2007 at 2:30pm (EST)

WHERE: Chateau Frontenac, Quebec

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of BioMS Medical with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2013)... -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: ... its expertise in opioid antagonists, today issued a letter ... updating shareholders on the Company,s progress in 2013. ... management team of Lightlake Therapeutics Inc. looks ahead to ... progress in 2013 and are eager for the opportunities ...
(Date:12/20/2013)... , 20 december 2013 Arsenal ... New York gevestigde private equity-firma ... gezondheidszorg en gespecialiseerde industriële ondernemingen, heeft vandaag ... de toonaangevende leverancier van software voor geneesmiddelontwikkeling ... consultancyservices voor de biofarmaceutische onderzoeks- en ontwikkelingsmarkt. ...
(Date:12/20/2013)... December 20, 2013 Hemostemix Ltd . ... trial steering committee to guide the company in optimizing all ... product, ACP-01, in patients with critical limb ischemia. ... surgery, the role of the Clinical Trial Steering Committee will ... the trial’s success. , “We are extremely honored with ...
(Date:12/19/2013)... Green Dot , a bioscience social ... has developed a compostable synthetic leather made with the ... leather combines the look and feel of high quality ... leather tanning or synthetic leather manufacturing. , Green Dot’s ... solvents or glues. It is free from phthalates, Bisphenol ...
Breaking Biology Technology:Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders 2Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders 3Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders 4Arsenal Capital Partners verwerft Certara, leider in geneesmiddelontwikkeling op basis van modellen 2Arsenal Capital Partners verwerft Certara, leider in geneesmiddelontwikkeling op basis van modellen 3Arsenal Capital Partners verwerft Certara, leider in geneesmiddelontwikkeling op basis van modellen 4Hemostemix Meets with Newly Formed Clinical Trial Steering Committee 2Hemostemix Meets with Newly Formed Clinical Trial Steering Committee 3Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic 2
... John Gee knows the Bay Area and Silicon Valley very ... own value proposition to building a thriving technology industry, and ... named president and CEO of the Information Technology Association ... Mortimore, who has been serving in place of former chief ...
... are being talked about again, but do we really need to ... workers better educated, better workers, or are they just cheaper to ... the cover story of this week's Information Week ... couple of years and could never get anything close to what ...
... Wisconsin's first large-scale biodiesel plant has officially opened with ... , , Sanimax Energy will operate the plant ... a variety of different raw materials, including beef tallow. ... transportation, employs 15 people. , ,Biodiesel, which can be ...
Cached Biology Technology:Wisconsin IT association names Gee president, CEO 2H-1B jobs: Where is the shortage of skilled workers? 2H-1B jobs: Where is the shortage of skilled workers? 3H-1B jobs: Where is the shortage of skilled workers? 4H-1B jobs: Where is the shortage of skilled workers? 5H-1B jobs: Where is the shortage of skilled workers? 6
(Date:12/20/2013)... Ariz. A group of researchers from Arizona State ... major advance in the study of human proteins that ... of the future. The work is being reported in ... the paper, "Serial femtosecond crystallography of G-protein-coupled receptors," the ... at room temperature the structure of G protein-coupled receptors ...
(Date:12/19/2013)... at The City College of New York have ... a semisolid form using low-calorie sugars as a ... alternatives to structured oil products produced using saturated/trans ... artery disease, obesity and diabetes. , The team, ... John, tested two sugar alcohol-based gelators, mannitol dioctanoate ...
(Date:12/19/2013)... The newly sequenced genome of the Amborella plant ... suddenly proliferated on Earth millions of years ago. The genome ... history of life on Earth: the origin of flowering plants, ... a paper by the Amborella Genome Sequencing Project ... the project, as well as implications for flowering plant research, ...
Breaking Biology News(10 mins):ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3CCNY chemists use sugar-based gelators to solidify vegetable oils 2The origin of flowers: DNA of storied plant provides insight into the evolution of flowering plants 2The origin of flowers: DNA of storied plant provides insight into the evolution of flowering plants 3The origin of flowers: DNA of storied plant provides insight into the evolution of flowering plants 4
... some parts of the body is more harmful than fat in ... animal models and now, they are able to visualize how much ... it. The method will be published in the April issue of ... the key benefits of this technique versus existing methods, like ex ...
... hypothesis posed by a University of Tennessee, Knoxville, associate professor ... arena. The hypothesis suggests some species are surviving by discarding ... The groundbreaking "Black Queen Hypothesis" got its name ... is to avoid "winning" the Queen of Spades (the Black ...
... A new gene that causes early-onset of Alzheimer,s disease has ... the Insert unit 1079 "Genetics of cancer and neuropsychiatric diseases" ... of 5 of 14 patients suffering from the disease, mutations ... production of a peptide involved in Alzheimer,s disease. The results ...
Cached Biology News:A University of Tennessee professor's hypothesis may be game changer for evolutionary theory 2A new gene thought to be the cause in early-onset forms of Alzheimer's disease 2
... anti-phospho-IRS1 (Tyr896) ... amino acid region encompassing the ... (Tyr896). Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
CCNI Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: